Martingale Asset Management L P Buys New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Martingale Asset Management L P purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 87,077 shares of the biopharmaceutical company’s stock, valued at approximately $1,731,000. Martingale Asset Management L P owned about 0.07% of Catalyst Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in CPRX. GAMMA Investing LLC lifted its stake in shares of Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares during the last quarter. nVerses Capital LLC purchased a new position in Catalyst Pharmaceuticals in the 3rd quarter worth approximately $50,000. Larson Financial Group LLC lifted its position in Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 2,994 shares during the last quarter. CWM LLC boosted its stake in shares of Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 3,549 shares during the period. Finally, Meeder Asset Management Inc. bought a new position in shares of Catalyst Pharmaceuticals in the second quarter worth approximately $70,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX opened at $22.07 on Monday. The firm has a market capitalization of $2.63 billion, a P/E ratio of 18.70, a P/E/G ratio of 3.40 and a beta of 0.75. The stock has a 50 day moving average price of $21.26 and a 200-day moving average price of $18.79. Catalyst Pharmaceuticals, Inc. has a 52-week low of $13.00 and a 52-week high of $24.27.

Insider Buying and Selling

In other news, Director Molly Harper sold 17,500 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. The trade was a 18.93 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on CPRX. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Stephens began coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 target price for the company. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Truist Financial upped their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, Citigroup lifted their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals has an average rating of “Buy” and an average target price of $31.14.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.